UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that it has entered into a definitive agreement under which UCB would acquire Neurona Therapeutics, including lead ...

UCB will pay $650m upfront and up to $500m in future milestones.

Belgian pharma company UCB (UCBJY) on Friday announced an agreement to acquire Neurona Therapeutics, a U.S.-based developer of cell therapies for neuronal diseases, for a total consideration of up to ...

After a recent streak of buyouts by some of Big Pharma's serial acquirers, Belgium's UCB is getting | The agreement fulfills ...

The takeover – which, if completed, will be the third acquisition for UCB this decade – involves an upfront payment of $650 ...

In a retrospective cohort, a clinical heuristic composed of eight binary variables helped identify which patients with medial temporal lobe epilepsy (MTLE) were best suited for stereotactic laser ...

Temporal lobe epilepsy, which results in recurring seizures and cognitive dysfunction, is associated with premature aging of brain cells. A new study from researchers at Georgetown University Medical ...

Seizures can be predicted more than 30 minutes before onset in patients with temporal lobe epilepsy, opening the door to a therapy using electrodes that could be activated to prevent seizures from ...